Roche launched imCORE, a global network of cancer immunotherapy centers of excellence.
On Nov. 15, 2016, Roche launched immunotherapy Centers of Research Excellence (imCORE), a global network of cancer researchers focused on developing new treatments. This network brings together scientific and clinical experts in cancer immunotherapy to collaborate in investigating new treatment approaches. The goal is to rapidly initiate pre-clinical and clinical research based on the latest scientific discoveries and to aggregate and share data to accelerate the search for cures. The imCORE Network will focus on identifying approaches to expand the number of people who benefit from cancer immunotherapy by exploring new ways to activate a person’s immune system to fight their cancer.
imCORE is a global network of basic and clinical scientists from 21 leading academic research institutions in cancer immunotherapy. These scientists will collaborate with scientists from Roche and Genentech with the goal of developing potential cancer cures. Roche is working in collaboration with the network on existing and new investigational medicines, diagnostic technologies, and emerging data. The network will also closely collaborate to identify and prioritize new treatment approaches and to conduct clinical trials to accelerate progress in the field. Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations related to cancer immunotherapy. This investment is incremental to Roche’s on-going research and development of investigational medicines and treatment approaches in the field of cancer immunotherapy.
Source: Roche
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.